Subtype-specific prognostic impact of TNIK in medulloblastoma
Franz-Leonard Klaus, Theoni Maragkou, Claire Delbridge, Charles G. Eberhardt, Ekkehard Hewer, Antonia Gocke, Ramin Radpour, Christian Mawrin, Carolin Mogler, Julia E. Neumann, Stefan Forster · 2026
Read Subtype-specific prognostic impact of TNIK in medulloblastoma by Franz-Leonard Klaus, Theoni Maragkou, Claire Delbridge, Charles G. Eberhardt, Ekkehard Hewer, Antonia Gocke, Ramin Radpour, Christian Mawrin, Carolin Mogler, Julia E. Neumann, Stefan Forster (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156172.txt.
Description
Franz-Leonard Klaus and ten colleagues test whether a signaling protein called TNIK can forecast outcomes in medulloblastoma, the most common malignant brain tumor of childhood. The disease splits into subgroups with very different odds. Some children do well; others relapse at high rates, and treatment itself leaves lasting harm.
TNIK helps run the Wnt signaling path and has been tied to other cancers. The team checked its levels in public tumor data, protein profiles, and stained tissue samples. Levels ran highest in Group 3 and Group 4 tumors. The meaning flipped by subgroup: high TNIK spelled worse survival in Group 4, yet better outcomes in SHH tumors. The authors propose it as a subgroup-aware marker.
Catalog record
| CREATOR | Franz-Leonard Klaus, Theoni Maragkou, Claire Delbridge, Charles G. Eberhardt, Ekkehard Hewer, Antonia Gocke, Ramin Radpour, Christian Mawrin, Carolin Mogler, Julia E. Neumann, Stefan Forster |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |